Kwan-Ho (Alex) Chung, Ph.D.

Alex Chung is a partner in the Intellectual Property Practice Group in the firm's Washington, D.C. office.

Areas of Practice

Alex’s intellectual property practice encompasses patent prosecution, counseling, and litigation in the areas of biotechnology, pharmaceuticals, chemicals, and medical devices. His extensive experience includes procuring, managing, evaluating, enforcing, and defending patents, and in providing strategic IP counsel to clients.

Alex advises on strategic patent portfolio development and management, global patent prosecution, as well as patentability, infringement, validity, and freedom-to-operate (FTO) investigation, and due diligence analysis on IP portfolios. He has successfully represented clients in patent actions involving biotechnology, pharmaceutical (including Hatch-Waxman litigation), chemical, and medical device patents in the federal district courts, the U.S. International Trade Commission (ITC), and the Patent Trial and Appeal Board (PTAB). He also has experience in representing medical device companies in trade secret and contract actions. His representations include U.S., European, Korean, and Japanese stealth mode and start-up companies to multi-national corporations in the biotechnology, pharmaceutical, chemical, and medical device industries.

Alex’s practice encompasses diverse life science fields, including antibody therapeutics (cell-penetrating Ab, bispecific Ab, ADC), nucleic acid therapeutics (RNAi, miRNA, circRNA, CRISPR genome editing, ASOs), cell and regenerative therapy (immunotherapy, CAR-T cells, stem cells), gene therapy (AAV, adenovirus, extracellular vesicles), targeted protein degradation (TPD) technology (PROTAC, molecular glue), immune-oncology, combination therapy, drug repurposing, peptides, enzyme therapeutics, small molecule pharmaceuticals, chemicals, molecular diagnostics and assays, and medical devices (AI-driven diagnostics, spinal devices, electromagnetic devices), directed to various indications including oncological, immunological, inflammatory, neurological, and infectious diseases.

Prior to attending law school, Alex worked as a postdoctoral fellow at the National Institutes of Health (NIH), where he investigated photoreceptor differentiation and designed switchable adeno-associated virus (AAV) gene therapy vectors for clinical trials. He is a co-inventor of a U.S. patent on microRNA-based RNA interference (RNAi) expression vector, which was commercially licensed to and is currently marketed by one of the largest U.S. suppliers of scientific reagents, instrumentation, and consumables.

Honors

Ones to Watch, Litigation - Patent Law; Patent Law, Best Lawyers, 2023

Media Mentions